REGN Earnings

ssume the completion of any business development transactions not completed as of the date of this press release 7 A reconciliation of full year 2026 GAAP to non-GAAP financial guidance is included below: Projected Range ($ in millions) Low High GAAP R&D $ 6,450 $ 6,680 Stock-based compensation expense (550) (580) Non-GAAP R&D (a) $ 5,900 $ 6,100 GAAP SG&A $ 2

g, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance, including GAAP and non-GAAP R&D, GAAP and non-GAAP SG&A, GAAP and non-GAAP gross margin on net product sales, GAAP and non-GAAP COCM, capital expenditures, and GAAP and non-GA

Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise. Regeneron uses its media and investor relations website and social media outlets to publish important info

Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise. Note Regarding Non-GAAP Financial Measures This Report references non-GAAP net income per diluted share, w

press release ** GAAP and non-GAAP amounts are equivalent as no non-GAAP adjustments are expected to be recorded 8 A reconciliation of full year 2026 GAAP to non-GAAP financial guidance is included below: Projected Range ($ in millions) Low High GAAP R&D $ 6,450 $ 6,680 Stock-based compensation expense 550 580 Non-GAAP R&D (a) $ 5,900 $ 6,100 GAAP SG&A $ 2,860

g, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance, including GAAP and non-GAAP R&D, GAAP and non-GAAP SG&A, GAAP and non-GAAP gross margin on net product sales, COCM, capital expenditures, and GAAP and non-GAAP ETR; the potent

Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise. Regeneron uses its media and investor relations website and social media outlets to publish important info

cting the healthcare industry; unanticipated expenses; the costs of developing, producing, and selling products; Regeneron's ability to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; Regeneron's estimates of market opportunities for Regeneron's Products and Regeneron's Product Candidat

gs • Goal to prevent myeloma by treating precursor conditions Multi-faceted approach including GIP/GLP-1 Prioritizing combo with Praluent (PCSK9): potential to achieve >50% LDL lowering along with weight loss, dosed via similarly-convenient weekly injection as leading GLP-1s REGN7508Cat: optimizes anticoagulation activity with reduced bleeding risk vs.

eclinical development Initiating olatorepatide combo with Praluent (PCSK9) in 2026: • Approved GLP-1s lower LDL-C by less than 10% • Combination to potentially achieve >50% LDL lowering along with weight loss • To be administered via similarly-convenient weekly injection as leading GLP-1s In-licensing of olatorepatide (dual GIP/GLP-1 receptor agonist) enables